Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers
Peak oxygen consumption (VO 2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO 2. We questioned the value of peak VO 2 in predicting outcome in patients treated with β-blockers. We reviewed the records of 127 patients...
Gespeichert in:
| Veröffentlicht in: | Journal of cardiac failure 2004-02, Vol.10 (1), p.15-20 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20 |
|---|---|
| container_issue | 1 |
| container_start_page | 15 |
| container_title | Journal of cardiac failure |
| container_volume | 10 |
| creator | Shakar, Simon F Lowes, Brian D Lindenfeld, Joann Zolty, Ronald Simon, Marc Robertson, Alastair D Bristow, Michael R Wolfel, Eugene E |
| description | Peak oxygen consumption (VO
2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO
2. We questioned the value of peak VO
2 in predicting outcome in patients treated with β-blockers.
We reviewed the records of 127 patients who had peak VO
2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO
2 hi) and ≤14 ml·kg·min (VO
2 lo). VO
2 hi had 109 patients and VO
2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO
2 and left ventricular ejection fraction were lower in VO
2 lo versus VO
2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO
2 lo versus 79% in VO
2 hi (
P
=
.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival.
Current peak VO
2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers. |
| doi_str_mv | 10.1016/S1071-9164(03)00593-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80161654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071916403005931</els_id><sourcerecordid>80161654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-7c08f7c493b2334cbdfa33205cbf55334df652f38b61b01a24c52b6f03ca62d33</originalsourceid><addsrcrecordid>eNqFkEuO1DAQhi0EYh5wBJBXCBaBcvxIeoXQCAakkUAC1pZdKdNmkrixHaCvxUE4E5npRixZVan0_VWqj7FHAp4LEObFRwGdaDbCqKcgnwHojWzEHXYqtGybXgl1d-3_IifsrJSvANAr6O6zE6E2xnQdnDL_gdw1Tz_3X2jmmOayTLsa08zdPPC0VEwT8TjzLblceXBxXDLxnauR5lo4bnOaI7px3POayVUa-I9Yt_z3r8aPCa8plwfsXnBjoYfHes4-v3n96eJtc_X-8t3Fq6sGpRG16RD60KHaSN9KqdAPwUnZgkYftF4nQzC6DbL3RngQrlWoW28CSHSmHaQ8Z08Oe3c5fVuoVDvFgjSObqa0FNuv2oTRagX1AcScSskU7C7HyeW9FWBv5NpbufbGnAVpb-VaseYeHw8sfqLhX-pocwVeHgBa3_weKduCqyekIWbCaocU_3PiD2hli0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80161654</pqid></control><display><type>article</type><title>Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shakar, Simon F ; Lowes, Brian D ; Lindenfeld, Joann ; Zolty, Ronald ; Simon, Marc ; Robertson, Alastair D ; Bristow, Michael R ; Wolfel, Eugene E</creator><creatorcontrib>Shakar, Simon F ; Lowes, Brian D ; Lindenfeld, Joann ; Zolty, Ronald ; Simon, Marc ; Robertson, Alastair D ; Bristow, Michael R ; Wolfel, Eugene E</creatorcontrib><description>Peak oxygen consumption (VO
2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO
2. We questioned the value of peak VO
2 in predicting outcome in patients treated with β-blockers.
We reviewed the records of 127 patients who had peak VO
2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO
2 hi) and ≤14 ml·kg·min (VO
2 lo). VO
2 hi had 109 patients and VO
2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO
2 and left ventricular ejection fraction were lower in VO
2 lo versus VO
2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO
2 lo versus 79% in VO
2 hi (
P
=
.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival.
Current peak VO
2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.</description><identifier>ISSN: 1071-9164</identifier><identifier>EISSN: 1532-8414</identifier><identifier>DOI: 10.1016/S1071-9164(03)00593-1</identifier><identifier>PMID: 14966770</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adrenergic beta-Antagonists - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; exercise ; Exercise Test ; Female ; Follow-Up Studies ; Heart Failure - drug therapy ; Heart Failure - metabolism ; Heart Failure - mortality ; heart transplantation ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Oxygen Consumption - drug effects ; Oxygen uptake ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Stroke Volume ; Survival Rate ; Treatment Outcome</subject><ispartof>Journal of cardiac failure, 2004-02, Vol.10 (1), p.15-20</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-7c08f7c493b2334cbdfa33205cbf55334df652f38b61b01a24c52b6f03ca62d33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1071916403005931$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14966770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shakar, Simon F</creatorcontrib><creatorcontrib>Lowes, Brian D</creatorcontrib><creatorcontrib>Lindenfeld, Joann</creatorcontrib><creatorcontrib>Zolty, Ronald</creatorcontrib><creatorcontrib>Simon, Marc</creatorcontrib><creatorcontrib>Robertson, Alastair D</creatorcontrib><creatorcontrib>Bristow, Michael R</creatorcontrib><creatorcontrib>Wolfel, Eugene E</creatorcontrib><title>Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers</title><title>Journal of cardiac failure</title><addtitle>J Card Fail</addtitle><description>Peak oxygen consumption (VO
2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO
2. We questioned the value of peak VO
2 in predicting outcome in patients treated with β-blockers.
We reviewed the records of 127 patients who had peak VO
2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO
2 hi) and ≤14 ml·kg·min (VO
2 lo). VO
2 hi had 109 patients and VO
2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO
2 and left ventricular ejection fraction were lower in VO
2 lo versus VO
2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO
2 lo versus 79% in VO
2 hi (
P
=
.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival.
Current peak VO
2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.</description><subject>Adolescent</subject><subject>Adrenergic beta-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>exercise</subject><subject>Exercise Test</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - mortality</subject><subject>heart transplantation</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Oxygen Consumption - drug effects</subject><subject>Oxygen uptake</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Stroke Volume</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1071-9164</issn><issn>1532-8414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEuO1DAQhi0EYh5wBJBXCBaBcvxIeoXQCAakkUAC1pZdKdNmkrixHaCvxUE4E5npRixZVan0_VWqj7FHAp4LEObFRwGdaDbCqKcgnwHojWzEHXYqtGybXgl1d-3_IifsrJSvANAr6O6zE6E2xnQdnDL_gdw1Tz_3X2jmmOayTLsa08zdPPC0VEwT8TjzLblceXBxXDLxnauR5lo4bnOaI7px3POayVUa-I9Yt_z3r8aPCa8plwfsXnBjoYfHes4-v3n96eJtc_X-8t3Fq6sGpRG16RD60KHaSN9KqdAPwUnZgkYftF4nQzC6DbL3RngQrlWoW28CSHSmHaQ8Z08Oe3c5fVuoVDvFgjSObqa0FNuv2oTRagX1AcScSskU7C7HyeW9FWBv5NpbufbGnAVpb-VaseYeHw8sfqLhX-pocwVeHgBa3_weKduCqyekIWbCaocU_3PiD2hli0Q</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>Shakar, Simon F</creator><creator>Lowes, Brian D</creator><creator>Lindenfeld, Joann</creator><creator>Zolty, Ronald</creator><creator>Simon, Marc</creator><creator>Robertson, Alastair D</creator><creator>Bristow, Michael R</creator><creator>Wolfel, Eugene E</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040201</creationdate><title>Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers</title><author>Shakar, Simon F ; Lowes, Brian D ; Lindenfeld, Joann ; Zolty, Ronald ; Simon, Marc ; Robertson, Alastair D ; Bristow, Michael R ; Wolfel, Eugene E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-7c08f7c493b2334cbdfa33205cbf55334df652f38b61b01a24c52b6f03ca62d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adrenergic beta-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>exercise</topic><topic>Exercise Test</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - mortality</topic><topic>heart transplantation</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Oxygen Consumption - drug effects</topic><topic>Oxygen uptake</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Stroke Volume</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shakar, Simon F</creatorcontrib><creatorcontrib>Lowes, Brian D</creatorcontrib><creatorcontrib>Lindenfeld, Joann</creatorcontrib><creatorcontrib>Zolty, Ronald</creatorcontrib><creatorcontrib>Simon, Marc</creatorcontrib><creatorcontrib>Robertson, Alastair D</creatorcontrib><creatorcontrib>Bristow, Michael R</creatorcontrib><creatorcontrib>Wolfel, Eugene E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiac failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shakar, Simon F</au><au>Lowes, Brian D</au><au>Lindenfeld, Joann</au><au>Zolty, Ronald</au><au>Simon, Marc</au><au>Robertson, Alastair D</au><au>Bristow, Michael R</au><au>Wolfel, Eugene E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers</atitle><jtitle>Journal of cardiac failure</jtitle><addtitle>J Card Fail</addtitle><date>2004-02-01</date><risdate>2004</risdate><volume>10</volume><issue>1</issue><spage>15</spage><epage>20</epage><pages>15-20</pages><issn>1071-9164</issn><eissn>1532-8414</eissn><abstract>Peak oxygen consumption (VO
2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO
2. We questioned the value of peak VO
2 in predicting outcome in patients treated with β-blockers.
We reviewed the records of 127 patients who had peak VO
2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO
2 hi) and ≤14 ml·kg·min (VO
2 lo). VO
2 hi had 109 patients and VO
2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO
2 and left ventricular ejection fraction were lower in VO
2 lo versus VO
2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO
2 lo versus 79% in VO
2 hi (
P
=
.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival.
Current peak VO
2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>14966770</pmid><doi>10.1016/S1071-9164(03)00593-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1071-9164 |
| ispartof | Journal of cardiac failure, 2004-02, Vol.10 (1), p.15-20 |
| issn | 1071-9164 1532-8414 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80161654 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adrenergic beta-Antagonists - therapeutic use Adult Aged Aged, 80 and over exercise Exercise Test Female Follow-Up Studies Heart Failure - drug therapy Heart Failure - metabolism Heart Failure - mortality heart transplantation Humans Male Middle Aged Multivariate Analysis Oxygen Consumption - drug effects Oxygen uptake Prognosis Proportional Hazards Models Retrospective Studies Stroke Volume Survival Rate Treatment Outcome |
| title | Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A49%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peak%20oxygen%20consumption%20and%20outcome%20in%20heart%20failure%20patients%20chronically%20treated%20with%20%CE%B2-blockers&rft.jtitle=Journal%20of%20cardiac%20failure&rft.au=Shakar,%20Simon%20F&rft.date=2004-02-01&rft.volume=10&rft.issue=1&rft.spage=15&rft.epage=20&rft.pages=15-20&rft.issn=1071-9164&rft.eissn=1532-8414&rft_id=info:doi/10.1016/S1071-9164(03)00593-1&rft_dat=%3Cproquest_cross%3E80161654%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80161654&rft_id=info:pmid/14966770&rft_els_id=S1071916403005931&rfr_iscdi=true |